P5-23-02: Clinicopathological Features of Young Patients Age <35 Years with Breast Cancer in Japan.

Abstract

Abstract Background: The aim of this study is to clarify clinicopathological features of breast cancer in young women. Materials and methods: Clinicopathological characteristics were compared between young (<35) patients and non-young (≥35) patients among 109,617 records of JBCS database registered from 2004 to 2009, and overall survival (10-yr OS) were calculated among 146,690 records from 1975 to 2000 with 8.6 years of median follow up period. Results: Clinicopathological factors of 2,982 young patients (2.7%) were compared with 106,295 non-young patients. Young patients had more familial history of breast cancer, more subjective symptom, less bilateral tumor, lower BMI, larger tumor, more inflammatory breast cancer, more positive node, less ER-positive, more HER2−positive, more triple-negative tumor, and more advanced TNM-stage. Comparison of clinicopathological factors between young and non-young patients with breast cancer Young patients were received more neoadjuvant chemotherapy and breast conserving therapy (BCT), compared with non-young patients. Comparison of treatments between young and non-young patients with breast cancer Eighty-percent of patients were received adjuvant therapy, among them, treatment rate of chemotherapy, molecular targeted therapy and radiation therapy was significantly higher in young patients than non-young patients. There was significant difference in 10-yr OS between young and non-young patients with Stage I-IIIA disease (Stage I 80% vs. 90%, IIA 78% vs. 85%, IIB 67% vs. 78%, IIIA 42% vs. 64%), but not with Stage IIIB and IIIC. Advanced TNM stage, lymph node metastasis and ER-negative tumor were significantly poorer prognostic factors for young patients by univariate analysis. Approximately 9% of young patients were at pregnancy at the time of diagnosis had more advanced disease and worse prognosis. Conclusions: We conclude that young patients with breast cancer have an advanced or an endocrine-unresponsive tumor and have unfavorable outcome. Advocacy for awareness of breast cancer to young women and development of new targeted therapy against advanced, HER2−positve and triple-negative tumor are important to improve the survival of young patients with breast cancer. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-23-02.